Bivalent Pfizer-BioNTech/Comirnaty vaccine available to those aged 12 and above from Dec 12

cnbc.com/2024/03/10/pfizer-is-betting-big-on-cancer-drugs-after-covid-decline.html

Mar 10

Pfizer is betting big on cancer drugs to turn business around after Covid decline – here's what to know

seekingalpha.com/article/4658260-pfizer-lost-all-of-its-covid-glory-but-dont-give-up-now

43

14

SeekingAlpha Dec 17 23

Pfizer: Lost All Of Its Covid Glory, But Don't Give Up Now: Pfizer remains committed to maintaining its dividend and posting solid profitability ...

7

Feb 19

Covid Vaccines Linked To Small Increase In Heart And Brain Disorders, Study Finds—But Risk From Infection Is Far Higher

forbes.com/sites/ariannajohnson/2024/02/19/covid-vaccines-linked-to-small-increase-in-heart-and-brain-disorders-study-finds-but-risk-from-infection-is-far-higher/

37

Jan 05

Paxlovid Cuts Covid Death Risk. But Those Who Need It Are Not Taking It.: With Covid deaths rising to about 1,500 per week, researchers question why Paxlovid use ...

nytimes.com/2024/01/04/health/paxlovid-covid-treatment.html

4

Jan 18

Ex-Pfizer employee convicted of insider trading on COVID drug trial: A former employee of Pfizer Inc (PFE.N) was convicted of insider trading on Thursday for ...

reuters.com/business/healthcare-pharmaceuticals/ex-pfizer-employee-convicted-insider-trading-covid-drug-trial-2024-01-18/

21

Nov 30 23

Texas AG Sues Pfizer Over Covid Vaccine Effectiveness: Attorney General Ken Paxton alleges Pfizer also attempted to silence critics of its vaccine.

forbes.com/sites/mollybohannon/2023/11/30/texas-ag-sues-pfizer-over-covid-vaccine-effectiveness/

145

Dec 13 23

Pfizer has turned to multi-billion deals, an internal restructuring and a massive cost-cutting program as the U.S

reuters.com/business/healthcare-pharmaceuticals/how-pfizer-is-fortifying-growth-beyond-covid-products-2023-12-13/

2

Mar 12

What To Know About Adcetris—Pfizer’s Cancer Drug Extended Survival For Patients With Common Lymphoma

forbes.com/sites/tylerroush/2024/03/12/what-to-know-about-adcetris-pfizers-cancer-drug-extended-survival-for-patients-with-common-lymphoma/

seekingalpha.com/article/4658881-pfizer-is-not-cheap-and-the-5-7-percent-yield-is-not-as-safe-as-you-might-think

17

5

SeekingAlpha Dec 20 23

Pfizer Is Not Cheap, And The 5.7% Yield Is Not As Safe As You Might Think: Is now the right time to invest in Pfizer's stock? Click here to find out why ...

1

Jan 19

Ex-Pfizer employee convicted of insider trading on COVID drug trial: A former employee of Pfizer Inc (PFE.N) was convicted of insider trading on Thursday for ...

reuters.com/business/healthcare-pharmaceuticals/ex-pfizer-employee-convicted-insider-trading-covid-drug-trial-2024-01-18/

111

18 6

Bloomberg

bloomberg.com/news/articles/2024-01-18/ex-pfizer-employee-convicted-of-insider-trading-on-covid-pill

Jan 18

Ex-Pfizer Employee Convicted of Insider Trading on Covid Pill: A former Pfizer Inc. employee was convicted of using confidential information about the company’s ...

16

Jan 04

Paxlovid Cuts Covid Death Risk. But Those Who Need It Are Not Taking It.: With Covid deaths rising to about 1,500 per week, researchers question why Paxlovid use ...

nytimes.com/2024/01/04/health/paxlovid-covid-treatment.html

347

152 1

SeekingAlpha Dec 16 23

Pfizer: The Bears Have Won This Round: An analysis of Pfizer's financial decisions, including overpaying for acquisitions, potential inventory write-downs ...

seekingalpha.com/article/4658187-pfizer-bears-have-won-this-round

seekingalpha.com/article/4658427-pfizer-stock-not-bad-time-to-start-position-add-weakness

1

SeekingAlpha Dec 18 23

Pfizer: Not A Bad Time To Start A Position And Add On Further Weakness: Pfizer offers a potential long-term investment with manageable debt and a solid portfolio ...

Investor's Business Daily

1 similar article

0

2

D

Jan 19

Ex-Pfizer Employee Netted $270,000 In Covid-Tied Insider Trading: A former Pfizer employee profited to the tune of $270,000 in an insider-trading scheme tied to ...

investors.com/news/technology/pfizer-stock-ex-employee-found-guilty-in-paxlovid-tied-insider-trading-scheme/

15

Dec 13 23

Pfizer Stock Sinks To 10-Year Low—Why Investors Have Soured On Covid-Era Giant: Shares of the Covid vaccine manufacturer are down about 50% this year.

forbes.com/sites/dereksaul/2023/12/13/pfizer-stock-sinks-to-10-year-low-why-investors-have-soured-on-covid-era-giant/

32

Jan 02

Pfizer Covid Drug Doses Set to Expire to Cost Europe $2.2 Billion: Stockpiles of Pfizer Inc.’s Paxlovid worth $2.2 billion are set to expire by the end of next ...

bloomberg.com/news/articles/2024-01-02/expiring-pfizer-covid-drug-doses-set-to-cost-europe-2-2-billion

25

Dec 13 23

How Pfizer is fortifying for growth beyond COVID products

reuters.com/business/healthcare-pharmaceuticals/how-pfizer-is-fortifying-growth-beyond-covid-products-2023-12-13/

26

Dec 19 23

Pfizer Covid Boosters Aren't Strong Enough Against Omicron: Pfizer is struggling because not enough people are getting annual Covid shots ...

bloomberg.com/opinion/articles/2023-12-19/pfizer-covid-boosters-aren-t-strong-enough-against-omicron

14

Dec 01 23

Pfizer Shares Drop After Drugmaker Drops Experimental Weight-Loss Pill: Pfizer Inc.’s second weight-loss setback this year is a warning sign that breaking into ...

bloomberg.com/news/articles/2023-12-01/pfizer-drops-twice-daily-weight-loss-pill-due-to-side-effects

8

Nov 14 23

Covid Rebound Hits 1 in 5 Paxlovid-Treated People in Small Study: Pfizer Inc.’s Paxlovid was linked to a high rate of Covid rebound in a small study that ...

bloomberg.com/news/articles/2023-11-14/covid-rebound-hits-1-in-5-paxlovid-treated-people-in-small-study

17

Feb 28

Older Americans advised to get another Covid shot this spring: Most Covid-19 deaths and hospitalizations last year were among people 65 years and older.

freemalaysiatoday.com/category/world/2024/02/29/older-americans-advised-to-get-another-covid-shot-this-spring/

1

Dec 06 23

Covid vaccination: Pfizer, Biontech and Moderna need no pity: Many people are still infected with the coronavirus. However, the willingness to be vaccinated has ...

nzz.ch/meinung/covid-impfung-pfizer-biontech-und-moderna-brauchen-kein-mitleid-ld.1768536

Quick Glance: Covid Vaccines: Pfizer, Biontech, Moderna's Remarkable Success

Leading vaccine manufacturers Pfizer, Biontech, and Moderna are experiencing significant success.

Last year, they generated double-digit billions with their mRNA vaccines against Sars-CoV-2.

Moderna alone had a revenue of over $19 billion, Biontech received around 17 billion euros, and Pfizer accumulated a revenue of $5.6 billion.

Pfizer made the most expensive acquisition in the pharmaceutical industry this year, totaling $43 billion.

6

Nov 13 23

Pfizer Stock Hits 3-Year Low—Down 50% From 2021 Peak: Excluding a brief early 2020 plunge, Pfizer shares are now trading at their lowest level since 2016.

forbes.com/sites/dereksaul/2023/11/13/pfizer-stock-hits-3-year-low-down-50-from-2021-peak/

35

9

The Wall Street Journal

wsj.com/articles/the-covid-vaccine-windfall-turns-on-pfizer-and-moderna-pandemic-booster-73b2903a

Nov 20 23

Opinion | The Covid Vaccine Windfall Turns for Pfizer and Moderna: Reduced demand and revenue for the jabs isn’t bad news. The industry is working as it’s ...

55

Dec 16 23

Pfizer struggles amid Covid decline: Pfizer's shares take a nosedive after a disappointing forecast for next year, revealing that its ambitious $43 billion ...

wionews.com/videos/pfizer-struggles-amid-covid-decline-670170

2

Dec 20 23

Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma

cnbc.com/2023/12/20/weight-loss-drugs-covid-downturn-pharma-had-a-year-full-of-firsts.html

forbesafrica.com/current-affairs/2023/11/14/pfizer-stock-hits-3-year-low-down-50-from-2021-peak/

22

15

Forbes Africa Nov 18 23

Pfizer Stock Hits 3-Year Low—Down 50% From 2021 Peak: TOPLINE Pfizer shares tumbled again Monday, continuing the pharmaceutical giant’s struggles tied to ...

Frankfurter Allgemeine Zeitung

3

1

A-

Mar 21

Pharma investment: courage is rewarded: The Mainz-based mRNA pioneer Biontech is a good example of how it can be worth taking risks in the volatile ...

faz.net/aktuell/wirtschaft/unternehmen/biontech-mut-wird-belohnt-19600734.html

ptaheute.de/aktuelles/2024/04/15/nach-corona-patienten-auf-parkinson-ueberwachen

Quick Glance: BioNTech Focuses on Cancer Drug Development after Revenue Plunge

BioNTech reported a significant drop in revenue and earnings in 2023 as it shifts focus towards cancer drug development.

The company aims for revenues between 2.5 billion to 3.1 billion euros in 2024.

BioNTech plans to launch its first oncology drug in 2026 and secure ten indication approvals by 2030.

Partner Pfizer anticipates a decline in sales for the COVID-19 vaccine, while BioNTech invests in scaling up its oncology business.

19 similar articles

0

PTAheute Apr 15

After corona: monitoring patients for Parkinson's?: SARS-CoV-2 also affects dopamine neurons and causes them to age - the nerve cells that die in Parkinson's ...

0

Mar 13

Covid patients who could benefit from paxlovid still aren’t getting it: During the pandemic, the federal government offered Americans a 5-day course of Paxlovid ...

texastribune.org/2024/03/13/grapevine-texas-covid-paxlovid/

0

Feb 10

Pfizer Covid jab to be sold in UK pharmacies: The drugs giant is in talks with high street chains to offer its vaccine privately from next month

thetimes.co.uk/article/pfizer-covid-jab-uk-sold-pharmacies-counter-vaccine-5jd6xtgfh

sfchronicle.com/health/article/it-s-last-week-order-free-at-home-covid-tests-18707712.php

2 similar articles

0

10 1

San Francisco Chronicle

B+

Mar 06

It’s the last week to order free at-home COVID tests by mail: Final call: Request your free COVID-19 tests by mail before the federal program ends Friday.

0

Dec 19 23

Covid variant JN.1 in India: Masks mandatory for everyone aged 60 & over in Karnataka Watch #LIVE here: youtube.com/live/c_fnaiUOd3w?feature=share #covid #JN1Variant #WION

0:00

Quick Glance: JN.1 Variant: Latest on Covid Developments

The JN.1 variant may be more transmissible, but does not cause more severe Covid cases.

Covid cases are on the rise, driven by the JN.1 variant, according to Dr. Mandy Cohen of the Centers for Disease Control and Prevention.

JN.1 accounts for about 21% of Covid cases in the US, up from 8% just two weeks ago, according to the CDC.

The World Health Organization has designated JN.1 as a 'variant of interest', indicating genetic changes that could enhance its spread.

145 similar articles

0

1

Central News Agency (Taiwan)

focustaiwan.tw/sci-tech/202402020014

Feb 02

Medigen to publish COVID-19 research on U.S. journal - Focus Taiwan: Taipei, Feb. 2 (CNA) A COVID-19 vaccine research from Taiwan-based Medigen Vaccine Biologics ...

romaniajournal.ro/society-people/pfizer-biontech-sued-romania-to-force-it-to-pay-for-the-anti-covid-vaccines-contracted-during-the-pandemic/

0

The Romania Journal Jan 19

Pfizer sued Romania on anti-Covid jabs: Pfizer - BioNTech sued Romania to force it pay for all the anti-Covid vaccines it contracted following the protocol ...

1 similar article

0

Kölnische Rundschau

C+

Dec 19 23

Dispute with Biontech: Federal Court declares Curevac's corona vaccine patent invalid

rundschau-online.de/wirtschaft/streit-mit-biontech-bundesgericht-erklaert-corona-impfstoffpatent-von-curevac-fuer-nichtig-705505

Quick Glance: Biontech Wins Lawsuit Against Curevac Patent

Crucial part of competition between Biontech and Curevac

Court rules in favor of Biontech in lawsuit against Curevac

Dispute over substantial amount of money between Biontech and Curevac

Biontech successfully invalidates fundamental Curevac patent

14 similar articles

0

DER AKTIONÄR

C

Jan 30

Pfizer: Profit slump of 93(!) percent: The American pharmaceutical giant Pfizer is feeling the effects of the reduced demand for Covid-19 medicines and vaccines.

deraktionaer.de/artikel/pharma-biotech/pfizer-gewinneinbruch-von-93-prozent-20349041.html

0

Jan 02

Expiring Pfizer Covid drug doses set to cost Europe $2.2bn: Soaring death counts spurred governments to invest heavily in Covid drug Paxlovid - but high vaccine ...

businesspost.ie/news/expiring-pfizer-covid-drug-doses-set-to-cost-europe-2-2bn/

0

Dec 01 23

Most vulnerable people urged to get Covid jabbed for winter: CRAVEN people at risk of becoming seriously ill or hospitalised with Covid are being urged to come ...

cravenherald.co.uk/news/23963113.vulnerable-people-urged-get-covid-jabbed-winter/

0

Dec 22 23

Covid infection rates double in weeks: Levels for Covid-19 have doubled in England and Scotland since the start of the month, with about one person in 24 ...

thetimes.co.uk/article/covid-infection-rates-double-in-weeks-rnsxk7qrk

0

Jan 01

Expired Pfizer Covid antiviral drugs set to cost Europe €2bn: Millions of Paxlovid pills have gone unused as tight controls restrict access

irishtimes.com/business/2024/01/01/expired-pfizer-covid-antiviral-drugs-set-to-cost-europe-2bn/

0

Dec 03 23

57.3pct increase in Covid cases: 48pct of cases aged 20-40, 98pct of them had mild symptoms.

malaysiakini.com/news/688777

0

Dec 19 23

Pfizer, BioNTech sue Poland and Hungary over Covid debts: EU countries ordered vaccines for their population through a joint purchase scheme.

freemalaysiatoday.com/category/business/2023/12/19/pfizer-biontech-sue-poland-and-hungary-over-covid-debts/

nzherald.co.nz/nz/covid-19-new-wave-of-infections-could-last-to-christmas/JBXNEJYWAVA3VKXOI43TFG7S5I/

0

1

The New Zealand Herald

A-

Dec 13 23

Covid-19: New wave of infections could last to Christmas: By RNZ Book a Covid-19 booster before Christmas if you’re at risk: That’s the message from health ...

seekingalpha.com/article/4655688-pfizer-stock-slimming-down-after-covid-franchise-obesity-pipeline-setbacks-reaffirm-buy

0

SeekingAlpha Dec 04 23

Pfizer: Slimming Down After COVID Franchise And Obesity Pipeline Setbacks: There is little Pfizer can do about the COVID franchise shortfall. Read more to see an ...

lep.co.uk/health/coronavirus/covid-autumn-booster-in-lancashire-last-chance-for-most-vulnerable-to-book-top-up-jab-4415280

0

Lancashire Evening Post

D+

Nov 19 23

Covid autumn booster in Lancashire: last chance for most vulnerable to book top-up jab

0

Nov 24 23

Singapore sees 2023's first child death from Covid-19: A child died from Covid-19 in October, making it the first such case this year ...

asiaone.com/singapore/singapore-sees-2023s-first-child-death-covid-19

0

7

japannews.yomiuri.co.jp

japannews.yomiuri.co.jp/society/coronavirus/20231123-151348/

Nov 23 23

Japan to Introduce Routine COVID-19 Vaccinations for Elderly: TOKYO (Jiji Press) — A special group of the health ministry Wednesday approved a plan to change ...

independent.ie/irish-news/surge-in-rsv-hospitalisations-in-babies-under-a-year-old-amid-concern-over-flu-and-covid-jab-uptake/a322528033.html

0

Irish Independent

C+

Nov 21 23

Surge in RSV hospitalisations in babies under a year old amid concern over flu and Covid jab uptake